Spravato is an FDA-approved treatment for depressed patients who have not had good success with medication management and therapy.
It is a nasal spray given in an office setting where patients are monitored for two hours. Patients come in to do treatments twice a week for four weeks, then once a week for four weeks, and then every two weeks after that. Over time, some treatments are spaced out even further.
Some patients will see a positive response in their symptoms in the first few treatments but it is also common to require a few weeks of treatment to see improvement. Patients often note improvement in mood, more energy, more enjoyment in activities, and more motivation.
Spravato is a prescription medicine used with an antidepressant taken by mouth for adults with TRD. Esketamine, the active ingredient in Spravato, has a unique mechanism that targets different pathways in the brain to those affected by other known antidepressants.
Unlike many other antidepressants, Spravato is administered via nasal spray, allowing it to be quickly absorbed. It works to rebalance certain chemical messengers in the brain that affect mood. Post-treatment observation is also necessary, ensuring patient safety and monitoring potential side effects.
Patients are in a private room and many patients rest or listen to music or podcasts during the two hours they are being monitored. APC's RN, Bud Green, will check in several times to see how the patient is doing and monitor blood pressure. After two hours, patients are evaluated one more time and then discharged. Because of the sedating effects, patients need someone to give them a ride home afterwards.